Remove Competition Remove Ethics Remove Government Remove Safety
article thumbnail

Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets

PM360

This can be especially important in the current global economic climate, where competition for market share is fierce, and access to new customers is critical for growth. This includes ensuring access and affordability of their products, which can positively impact their environmental social governance (ESG) score and reputation.

article thumbnail

Challenges in the Medical Sales Industry

MedReps

Often we’re lucky if we even get to see our physicians, let alone overcome their objections regarding insurance coverage and competitive claims. On the other hand, if your product is similar to the competition, get your physician’s attention with your product’s affordability and ease of use.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

Let’s dive into the current state of the pharma industry and learn more about what your team can do to stay ahead of the curve and the competition. More convenience and safety? PharmaKinnex’s multi-channel marketing approach gets the message across with clarity and consistency, breaking through the noise of the competition.

Pharma 52
article thumbnail

ESG considerations in Europe and Asia: social inclusion – the new diversity frontier in life sciences

European Pharmaceutical Review

This evolving focus is clearly visible in the growing emphasis now placed by many global businesses on environmental, social and governance (ESG) issues – and especially the ‘social’ element. ESG is an umbrella term for the tools used to measure the sustainability and ethical impact of a business. The broad landscape.

article thumbnail

Legal challenges put off label use of gender affirming care drugs in jeopardy

Pharmaceutical Technology

However, health specialists refute most safety concerns for the use of drug classes as part of gender affirming care, citing years of research and care. As these drugs are not licensed for the specific indication of gender-affirming care, collecting safety data on off-label use is not viewed as a priority.

Ethics 144